Volition Extends Global Reach of its Clinical Trial Program

ISNES, Belgium, July 10, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its already impressive clinical trial program with the execution of additional agreements to conduct large-scale colorectal cancer research studies across the Asia Pacific Region. These multi-country, multi-center and multi-ethnic Asian subject cohorts are in addition to the approximate 45,000 European subject cohorts and the 13,500 plus U.S. subject cohorts that are already part of existing studies and further demonstrate Volition's commitment to commercializing its Nu.Qtm platform globally through collaborating with world-renowned institutions and key opinion leaders.

In accordance with the previously announced memoranda of understanding, Volition has executed agreements with the prestigious National Taiwan University ("NTU") to conduct two studies under the supervision of Professor Han-Mo Chiu, Clinical Professor, Department of Internal Medicine of NTU, and Professor Takahisa Matsuda, Director of Cancer Screening Center, National Cancer Screening Hospital, Tokyo, Japan who will act as Co-Principal Investigator.

The first trial will be a large-scale study in the Asia Pacific Region, including 5,000 asymptomatic colorectal cancer screening subjects. The second trial will include up to 2,000 symptomatic colorectal cancer patients. These studies are being conducted to test and validate Volition's proprietary Nu.Qtm platform for the detection and diagnosis of colorectal cancer for marketing, rather than for regulatory purposes.

Professor Chiu commented, "The early detection of colorectal cancer could benefit the survival rate of patients significantly. There is a clear need for a product which not only has high accuracy but is also easy to use and affordable, such as a routine blood test. I very much look forward to collaborating with Volition in evaluating its Nu.Qtm technology platform."

In addition to these large-scale studies with NTU, Volition has also recently executed an agreement for a 719-subject study in collaboration with Professor Khay Guan Yeoh of the National University of Singapore. The study in Singapore gives an added dimension of applicability in different Asian ethnic groups by leveraging on the multi-ethnic population in Singapore.

"We are delighted to be working with such renowned institutions and prominent thought leaders," commented Dr. Jasmine Kway, Chief Executive Officer, Singapore Volition. "At a cost of approximately $2.55 million payable over three years, these large-scale studies are in line with Volition's other great value studies and demonstrate our commitment to conducting large yet cost-effective trials worldwide to drive the acceptance of our products. These studies are pivotal for Volition's strategy for the Asia Pacific Region where incidence of colorectal cancer is increasing."

Ongoing Clinical Studies

About Volition

Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers.  The tests are based on the technology platform of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively.  Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.  Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website https://volitionrx.com/
or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media/Investor Contacts
Louise Day, Chief Marketing & Communications Officer
[email protected] 
+44 (0)7557 774620
Scott Powell, Executive Vice President, Investor Relations
[email protected]
+1 (646) 650 1351
Joseph Green, Edison Advisors
[email protected] 
+1 (646) 653 7030

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ®, Nu.Qtm and Hypergenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

SOURCE VolitionRx Ltd